Cannabis, marijuana and Hemp stock news from Investorideas.com plus daily cannabis #potcasts - Investor Ideas #Potcasts #Cannabis News and Stocks on the Move
MJ Freeway Reports Cannabis Retail Sales for
April 20 "4/20" Holiday Exceeded $45M
DENVER - April 26, 2017 (Investorideas.com Newswire and
www.420cannabisinvestorideas.com) MJ Freeway, the cannabis industry's leading
provider of seed-to-sale traceability solutions, reports that cannabis retail
sales for the largest marijuana holiday exceeded $45 million, a 20% increase
compared to the 2016 holiday.
Prior to the holiday, MJ Freeway predicted a 20% increase in
retail cannabis sales and a 10% increase in customer traffic. MJ Freeway's
predictions and reports are based on sales data figures compiled through
analysis of their majority cannabis retail market share.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure:Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
New Frontier Data 2017 #Cannabis Industry
Annual Report Reveals Medical Cannabis Patients Outspend Adult Use Consumers
Nearly 3 to 1 in Multi-billion-dollar U.S. Market
Cannabis Industry Presents Unprecedented
Consumer Market Opportunity
WASHINGTON. DC - April 26, 2017 (Investorideas.com Newswire and
www.420cannabisinvestorideas.com) New Frontier Data, the authority in business
intelligence for the cannabis industry, has released, The Cannabis Industry
Annual Report: 2017 Legal Marijuana Outlook. The report is the first to reveal
the growing discrepancy in spending between recreational and medical consumers
in the fastest growing industry in the country; months ahead of California, the
largest consumer economy in the U.S. and 6th largest in the world, activating
its adult-use market in 2018 after being the first state to legalize medical
use in 1996.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure:Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Canadian #Cannabis Stock News: Beleave (CSE:
BE) (CSE: BE.CN) and Dr. Mohit Bhandari Begin Clinical Research Program to
Investigate Therapeutic Use of Cannabinoids for Musculoskeletal Disorders
TORONTO, ON - April 26, 2017 (Investorideas.com Newswire) Beleave
Inc. ("Beleave") (CSE: BE) (CSE: BE.CN) (CNSX: BE) is pleased to
announce that it will begin a clinical research program with Dr. Mohit
Bhandari, to investigate the therapeutic use of cannabinoids for management of
pain in musculoskeletal disorders. In North America, Europe, and Australia,
chronic non-cancer pain is a large contributor to morbidity, affecting as much
as 30% of the population. Musculoskeletal disorders can be triggering events
that lead to the development of chronic pain in up to 40% of chronic pain
cases. Options for pain management in musculoskeletal disorders, both surgical
and non-surgical, remain limited.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure:Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Canadian
#Cannabis Stock News: Abattis (CSE: $ATT) (OTCQB: $ATTBF) Signs Exclusive
Distribution Agreement for Proprietary Extraction Technology
Vancouver, British Columbia - April
26, 2017 (Newsfile Corp.) (Investorideas.com Newswire) Abattis Bioceuticals
Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or
"Abattis") is pleased to announce it has signed an exclusive
distribution agreement effective April 20, 2017 (the "Agreement")
with Suzhou Raybot Material Tech Corp. ("Raybot"). The Agreement
allows Abattis to use Raybot's proprietary extraction technology and to
exclusively sell the extraction equipment and services.
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure:Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
Lemonhaze.com Reports WA Retail Marijuana
Sales Spike 79% on 4/20
SEATTLE - April 24, 2017 (Investorideas.com Newswire)
Lemonhaze.com, the leading real-time provider of cannabis data, released live
market data for April 20, 2017, the de facto "black Friday of the cannabis
market." "April 20th is the fourth biggest sales day of the year for
Washington marijuana retailers behind only New Year's Eve, Christmas Eve, and
the day before Thanksgiving," remarked Brian Yauger, president of
lemonhaze.com.
For April 20, 2017, lemonhaze.com calculated a 79 percent jump
in daily sales revenue, compared to the average daily sales for the first 19
days of April. Lemonhaze also calculated a 73 percent jump in daily sales
compared to the average Thursday in 2017. "420 was a monster success this
year. We had all hands on deck and still barely kept up with it. It's the best
holiday of the year," according to Alden Linn, owner of World of Weed
retail shop in Tacoma.
Recreational marijuana is one of the fastest-growing industries
in the county. Currently Washington State has 365 active retailers compared to
251 this time last year. In the last year, there has been a 45 percent increase
in the number of cannabis retail stores in Washington, and a 61 percent
increase in sales between April 20, 2016 and April 20, 2017.
According to retail owner Ian Eisenberg of Uncle Ike's,
Washington's second largest retailer in 2016, "420 was bonkers! Two years
ago, it was primarily pot heads celebrating 420. This year it was moms, dads,
grannies and everyone else excited about getting high! God bless America!"
About
Lemonhaze.com
Lemonhaze.com publishes hourly live charts of the top selling
cannabis products in Washington State across nine categories including packaged
flower, pre-rolls, cartridges and edibles. The charts lock at 4:20pm each day.
Lemonhaze.com sources information via live data connections with well over 100
licensed cannabis retailers, processors, and producers in Washington State.
Contacts
Lemonhaze.com
Brian Yauger
206-305-8796
brian@lemonhaze.com
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure:Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
Medical Marijuana Stock News; Cronos Group
(TSX VENTURE: $MJN) Provides Update on Minority Investments
TORONTO, ON - April 24, 2017 (Investorideas.com Newswire) Cronos
Group Inc. (formerly PharmaCan Capital Corp.) (TSX VENTURE: MJN)
("Cronos", or the "Company") is providing an update on its
investments in Whistler Medical Marijuana Corporation ("Whistler"),
The Hydropothecary Corporation ("Hydropothecary"), ABcann Medicinals
Inc. ("ABcann"), Evergreen Medicinal Supply Inc.
("Evergreen"), and CannMart Inc. ("CannMart").
Whistler
As previously announced, Cronos recently completed its
additional equity investment in Whistler and maintained the Company's 21.5%
equity position. This additional capital will assist Whistler with their
announced 65,000 square foot expansion in Pemberton, British Columbia. This
expansion is expected to be completed by spring of 2018 in advance of
recreational legalization in Canada.
Hydropothecary
Cronos holds a minority equity position in Hydropothecary, which
recently started trading on the Toronto Venture Exchange on March 21st, 2017
under the symbol "THCX". Hydropothecary is the only licensed producer
in Quebec and is currently operating and expanding on its 80 acres of land near
Gatineau, QC.
ABcann
ABcann recently announced a reverse takeover with Panda Capital
Inc., which shall constitute ABcann's qualifying transaction. ABcann is
licensed to produce up to 625 kg per year at their flagship Vanluven facility
situated near Napanee, ON. Abcann recently supplemented its executive and
advisory teams and undertook significant expansion initiatives at both their
existing licensed facility as well as their expansion property.
Evergreen
Cronos completed its subscription for a second tranche of shares
of Evergreen for $100,000 and exercised its option to acquire an additional 5%
of the equity for $500,000, for a total additional investment of $600,000.
Cronos satisfied this obligation in part by directing that debt owed by
Evergreen be applied as payment for the equity and delivered the remainder of
the payment in cash. However, Evergreen claims that Cronos is not entitled to
any interest in Evergreen and has rejected Cronos' payment.
Cronos filed a statement of claim in the Supreme Court of
British Columbia and intends to vigorously pursue the enforcement of its rights
to acquire equity in Evergreen in addition to Evergreen's repayment of the
debt. While there can be no assurance that Cronos will acquire its equity in
Evergreen, management believes that Cronos is entitled to the relief sought in
its statement of claim.
CannMart
Cronos no longer intends to retain an investment in CannMart and
CannMart has agreed to return the $25,000 previously paid by Cronos in respect
of its proposed equity investment in CannMart.
About
Cronos Group
Cronos Group, is a geographically diversified and vertically
integrated cannabis company that operates two wholly-owned Licensed Producers
("LPs") regulated within Health Canada's Access to Cannabis for
Medical Purposes Regulations (the "ACMPR") and holds a portfolio of
minority investments in other Licensed Producers. The company's flagship LPs,
Peace Naturals Project Inc. (Ontario), and In The Zone Produce Ltd. (British
Columbia) are collectively situated on over 125 acres of agricultural land and
are currently licensed to produce 2,600 kg of cannabis on an annual basis. The
Company also holds minority equity positions in Licensed Producers Whistler
Medical Marijuana, Hydropothecary, and Abcann. Cronos Group is focused on
building an iconic brand portfolio, providing patients with compassionate and
personalized care, and creating value for our shareholders.
Forward-looking statements
This news release may contain "forward-looking
information" and "forward-looking statements" within the meaning
of applicable Canadian securities legislation. All information contained herein
that is not clearly historical in nature may constitute forward-looking
information. Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by management, are
inherently subject to significant business, economic and competitive risks,
uncertainties and contingencies that may cause actual financial results,
performance or achievements to be materially different from the estimated
future results, performance or achievements expressed or implied by those
forward-looking statements and the forward-looking statements are not
guarantees of future performance. Except as required by law, Cronos Group
disclaims any obligation to update or revise any forward-looking statements.
Readers are cautioned not to put undue reliance on these forward-looking
statements. This news release contains information obtained by Cronos Group
from third parties. Cronos Group believes such information to be accurate but
has not independently verified such information.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure:Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
#Cannabis
Experts Join True Leaf (CSE: $MJ) (FSE: $TLA) Team for Final Marijuana
Licensing Review Stage
Experts will advise on production
facility design and build, security, and product testing before pre-license
inspection
Vancouver, British Columbia - April
24, 2017 (Newsfile Corp.) (Investorideas.com Newswire) True Leaf Medicine Inc.
(True Leaf), a division of True Leaf Medicine International Ltd. (CSE: MJ)
(FSE: TLA), has engaged a number of cannabis experts to guide the company
through the final stage in Health Canada's review of its application for a
license to produce marijuana in Canada.
Experts from industry-leading Pipe
Dreemz Inc., Protect-IP Global Solutions Inc., Eurofins Scientific, and Ample
Organics will be working with True Leaf over the next few weeks to prepare a
review package for submission to Health Canada under the Access to Cannabis for
Medical Purposes Regulations (ACMPR) application process.
Health Canada recently upgraded the
Marihuana for Medical Purposes Regulations (MMPR) application process to the
ACMPR licensing program, so the experts will be working with True Leaf to
update its original MMPR application to ensure True Leaf meets or exceeds the
new compliance measures.
"True Leaf is excited to have
Pipe Dreemz, Protect-IP, Eurofins, and Ample Organics provide their expertise
at this critical stage in the ACMPR review process," said True Leaf CEO
Darcy Bomford. "We sought out experts from these companies because several
of their clients have already been successful in the ACMPR process."
True Leaf has engaged Pipe Dreemz CEO
George Routhier, a premier consultant to companies going through Health
Canada's Marihuana for Medical Purposes Regulations (MMPR) or ACMPR process
since 2012. Mr. Routhier helps his clients navigate the complexities of the
licensing process, specifically the design, construction, and operating
procedures of marijuana production facilities. Pipe Dreemz is currently
advising clients with over $150 million in production facilities under
construction in Canada.
Protect-IP will advise True Leaf on
the Physical Safety Integration of its planned production facility.
Protect-IP's engineering team has worked with companies in all phases of the
licensing process, and will work with True Leaf on developing procedures for
control systems, alarm systems, and CCTV using IP technology to ensure True
Leaf builds and operates a safe and secure production facility.
Eurofins, a leading international
group of laboratories with more than 22,000 employees across 225 sites in 39
countries, will help True Leaf test its marijuana products to ensure it
complies with Health Canada regulations. Eurofins works with the
pharmaceutical, food, environmental, and consumer products industries on a
wide-range of scientific testing and support services.
True Leaf has also engaged Ample
Organics, the most widely adopted seed-to-sale reporting system among Canada's
licensed marijuana producers.
"We are pleased to be working
with True Leaf, a late stage ACMPR applicant," said Pipe Dreemz CEO George
Routhier. "Darcy and his team have chosen to accelerate their final push
to the finish line, and together we expect to receive their pre-license
inspection in the very near future."
About True Leaf:
True Leaf Medicine International
Ltd., through its wholly-owned subsidiary 'True Leaf Pet', has entered the
$104.9 billion global pet care industry with a line of hemp-focused pet chews
and supplements marketed through natural pet health and veterinary channels in
Canada, the United States and Europe. The company has also filed an application
under Health Canada's Access to Cannabis for Medical Purposes Regulations
(ACMPR) to become a Canadian licensed producer through its 'True Leaf Medicine'
subsidiary. It has passed through the security screening process of Health
Canada's review and is currently in the final review stage before the
'pre-licensing inspection' approval.
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure:Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
